What is evogene company?
About us. Evogene (NASDAQ, TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.
Is evogene a buy?
Evogene has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Will evogene stock go up?
Stock Price Forecast The 3 analysts offering 12-month price forecasts for Evogene Ltd have a median target of 10.00, with a high estimate of 15.00 and a low estimate of 9.00. The median estimate represents a +693.65% increase from the last price of 1.26.
Should I buy EVGN stock?
The financial health and growth prospects of EVGN, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
Will Aim stock go up?
Given the current short-term trend, the stock is expected to rise 9.46% during the next 3 months and, with a 90% probability hold a price between $0.78 and $1.31 at the end of this 3-month period.
Should I sell aim?
AIM ImmunoTech Inc. holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Is LifeMD stock a buy?
LifeMD has received a consensus rating of Buy.
Is Aim a buy?
Maxim Group is very positive about AIM and gave it a “Buy” rating on Feb 09, 2021. The price target was set to $2.00….Predicted Opening Price for AIM ImmunoTech Inc. of Friday, March 25, 2022.
| Fair opening price March 25, 2022 | Current price |
|---|---|
| $1.11 | $1.10 (Undervalued) |
What does Evogene do?
Investor Relations Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN) is a leading computational biology company targeting to revolutionize life-science product development.
Who is Evogene’s new CEO?
Mr. Lazer Bezdin was appointed as Evogene’s Chief Operating Officer in July 2021, bringing more than 20 years of business experience, mainly in Pharmaceuticals and Clean-Tech industries. His experience includes 10 years in various roles in Teva Pharmaceuticals (NASDAQ: TEVA).
Who is the director of Evogene?
Dr. Percy earned a bachelor’s degree in pharmacology at the University of Liverpool, as well as a master’s degree in toxicology and a doctorate in biochemistry at the University of Birmingham. Mr. Leon Y. Recanati has served as Evogene director since 2005.
What are Evogene’s main subsidiaries?
Evogene’s main subsidiaries utilize the technological engines to develop novel products as follows: human microbiome-based therapeutics by Biomica Ltd ., medical cannabis by Canonic Ltd ., ag-chemicals by AgPlenus and ag-biologicals by Lavie Bio Ltd . Evogene shares traded 1.63% higher at $1.25 per share at the time of writing Tuesday morning.